Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04099966 · ClinicalTrials.gov registry record · Phase 2
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
A Phase 2 study of Sickle Cell Disease and Non-Hodgkin Lymphoma, sponsored by Mitchell Cairo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04099966 is a Phase 2 study of Sickle Cell Disease and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Mitchell Cairo. The registered enrollment target is 20 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04099966, a Phase 2 study of Sickle Cell Disease and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Mitchell Cairo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
Conditions Studied
Interventions
- DRUG alpha beta depletion
Study Locations (1)
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04099966
The ClinicalTrials.gov registry entry for NCT04099966 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The listed sponsor is Mitchell Cairo, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which alpha beta depletion is the first listed.
NCT04099966 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04099966 about?
NCT04099966 is a clinical study titled "AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion". Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
What is the current status of trial NCT04099966?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-04-01. Estimated completion is 2027-12-31.
What conditions does trial NCT04099966 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Leukemia, Severe Aplastic Anemia.
What interventions are being tested in trial NCT04099966?
The interventions under investigation include: alpha beta depletion (DRUG).
Who is sponsoring clinical trial NCT04099966?
This trial is sponsored by Mitchell Cairo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04099966 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.